Blue Fin Group: Oncology Spotlight


Blue Fin Group completed a quantitative survey and qualitative in-depth interviews focusing on the evolution of payer management for oncology therapies. The research was conducted with payers overseeing approximately 238 million commercial, Medicare, and Medicaid lives.

Topics discussed within the interviews expand beyond the scope of insights characterized here and consist of:

  • Identification of top cancer types by drug spend/budget and by management focus
  • Payer approach to oncology management – how products are grouped or not grouped – for purposes of management and P&T review
  • Objectives of oncology management and how it is assessed and measured
  • Identification of obstacles to managing oncology
  • Role of biosimilars in oncology management – today and in the future 
  • Current approach to managing NSCLC targeted and immunotherapies • Role of diagnostics in oncology management



Kerri Fortier
Principal Consultant
Blue Fin Group, an IntegriChain Company

Jonny Clark
Blue Fin Group, an IntegriChain Company


adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article